Literature DB >> 22026501

Ventral midbrain correlation between genetic variation and expression of the dopamine transporter gene in cocaine-abusing versus non-abusing subjects.

Yanhong Zhou1, Sharon K Michelhaugh, Carl J Schmidt, Jun S Liu, Michael J Bannon, Zhicheng Lin.   

Abstract

Altered activity of the human dopamine transporter gene (hDAT) is associated with several common and severe brain disorders, including cocaine abuse. However, there is little a priori information on whether such alterations are due to nature (genetic variation) or nurture (human behaviors such as cocaine abuse). This study investigated the correlation between seven markers throughout hDAT and its mRNA levels in postmortem ventral midbrain tissues from 18 cocaine abusers and 18 strictly matched drug-free controls in the African-American population. Here, we show that one major haplotype with the same frequency in cocaine abusers versus drug-free controls displays a 37.1% reduction of expression levels in cocaine abusers compared with matched controls (P=0.0057). The most studied genetic marker, variable number tandem repeats (VNTR) located in Exon 15 (3'VNTR), is not correlated with hDAT mRNA levels. A 5' upstream VNTR (rs70957367) has repeat numbers that are positively correlated with expression levels in controls (r(2)=0.9536, P=0.0235), but this positive correlation disappears in cocaine abusers. The findings suggest that varying hDAT activity is attributable to both genetics and cocaine abuse.
© 2011 The Authors, Addiction Biology © 2011 Society for the Study of Addiction.

Entities:  

Keywords:  Addiction; DAT; epigenetics; expressional variation; pharmacogenomics; postmortem

Mesh:

Substances:

Year:  2011        PMID: 22026501      PMCID: PMC3270208          DOI: 10.1111/j.1369-1600.2011.00391.x

Source DB:  PubMed          Journal:  Addict Biol        ISSN: 1355-6215            Impact factor:   4.280


  33 in total

1.  Haploview: analysis and visualization of LD and haplotype maps.

Authors:  J C Barrett; B Fry; J Maller; M J Daly
Journal:  Bioinformatics       Date:  2004-08-05       Impact factor: 6.937

Review 2.  Algorithms for inferring haplotypes.

Authors:  Tianhua Niu
Journal:  Genet Epidemiol       Date:  2004-12       Impact factor: 2.135

3.  Dopamine transporter (SLC6A3) 5' region haplotypes significantly affect transcriptional activity in vitro but are not associated with Parkinson's disease.

Authors:  Samir N Kelada; Paola Costa-Mallen; Harvey Checkoway; Christopher S Carlson; Terri-Smith Weller; Phillip D Swanson; Gary M Franklin; W T Longstreth; Zahra Afsharinejad; Lucio G Costa
Journal:  Pharmacogenet Genomics       Date:  2005-09       Impact factor: 2.089

4.  Analysis of cocaine and metabolites in brain using solid phase extraction and full-scanning gas chromatography/ion trap mass spectrometry.

Authors:  A Hernandez; W Andollo; W L Hearn
Journal:  Forensic Sci Int       Date:  1994-05-13       Impact factor: 2.395

5.  Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter.

Authors:  R R Gainetdinov; F Fumagalli; S R Jones; M G Caron
Journal:  J Neurochem       Date:  1997-09       Impact factor: 5.372

6.  Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter.

Authors:  E Bezard; C E Gross; M C Fournier; S Dovero; B Bloch; M Jaber
Journal:  Exp Neurol       Date:  1999-02       Impact factor: 5.330

7.  Identification of additional variants within the human dopamine transporter gene provides further evidence for an association with bipolar disorder in two independent samples.

Authors:  T A Greenwood; N J Schork; E Eskin; J R Kelsoe
Journal:  Mol Psychiatry       Date:  2006-02       Impact factor: 15.992

8.  Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with parkinsonism, and Alzheimer's disease.

Authors:  J N Joyce; G Smutzer; C J Whitty; A Myers; M J Bannon
Journal:  Mov Disord       Date:  1997-11       Impact factor: 10.338

9.  Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter.

Authors:  B Giros; M Jaber; S R Jones; R M Wightman; M G Caron
Journal:  Nature       Date:  1996-02-15       Impact factor: 49.962

10.  A common haplotype of the dopamine transporter gene associated with attention-deficit/hyperactivity disorder and interacting with maternal use of alcohol during pregnancy.

Authors:  Keeley-Joanne Brookes; Jon Mill; Camilla Guindalini; Sarah Curran; Xiaohui Xu; Jo Knight; Chih-Ken Chen; Yu-Shu Huang; Vaheshta Sethna; Eric Taylor; Wai Chen; Gerome Breen; Philip Asherson
Journal:  Arch Gen Psychiatry       Date:  2006-01
View more
  16 in total

1.  Human dopamine transporter gene: differential regulation of 18-kb haplotypes.

Authors:  Ying Zhao; Nian Xiong; Yang Liu; Yanhong Zhou; Nuomin Li; Hong Qing; Zhicheng Lin
Journal:  Pharmacogenomics       Date:  2013-09       Impact factor: 2.533

2.  Increased heat shock protein 70 gene expression in the brains of cocaine-related fatalities may be reflective of postdrug survival and intervention rather than excited delirium.

Authors:  Magen M Johnson; James A David; Sharon K Michelhaugh; Carl J Schmidt; Michael J Bannon
Journal:  J Forensic Sci       Date:  2012-07-16       Impact factor: 1.832

3.  Transcriptomic profiling of the ventral tegmental area and nucleus accumbens in rhesus macaques following long-term cocaine self-administration.

Authors:  Eric J Vallender; Dharmendra B Goswami; Nina M Shinday; Susan V Westmoreland; Wei-Dong Yao; James K Rowlett
Journal:  Drug Alcohol Depend       Date:  2017-03-18       Impact factor: 4.492

4.  Valproate increases dopamine transporter expression through histone acetylation and enhanced promoter binding of Nurr1.

Authors:  Ashley L Green; Le Zhan; Aseel Eid; Helmut Zarbl; Grace L Guo; Jason R Richardson
Journal:  Neuropharmacology       Date:  2017-07-22       Impact factor: 5.250

5.  Functional effects of dopamine transporter gene genotypes on in vivo dopamine transporter functioning: a meta-analysis.

Authors:  S V Faraone; T J Spencer; B K Madras; Y Zhang-James; J Biederman
Journal:  Mol Psychiatry       Date:  2013-09-24       Impact factor: 15.992

6.  Increased Nigral SLC6A3 Activity in Schizophrenia Patients: Findings From the Toronto-McLean Cohorts.

Authors:  James L Kennedy; Nian Xiong; Jinlong Yu; Clement C Zai; Jennie G Pouget; Jie Li; Kefu Liu; Hong Qing; Tao Wang; Eden Martin; Deborah L Levy; Zhicheng Lin
Journal:  Schizophr Bull       Date:  2015-12-26       Impact factor: 9.306

7.  Intragenic Transcriptional cis-Antagonism Across SLC6A3.

Authors:  Ying Zhao; Jinlong Yu; Juan Zhao; Xiaowu Chen; Nian Xiong; Tao Wang; Hong Qing; Zhicheng Lin
Journal:  Mol Neurobiol       Date:  2018-09-27       Impact factor: 5.590

8.  AZI23'UTR Is a New SLC6A3 Downregulator Associated with an Epistatic Protection Against Substance Use Disorders.

Authors:  Kefu Liu; Jinlong Yu; Juan Zhao; Yanhong Zhou; Nian Xiong; Jie Xu; Tao Wang; Richard L Bell; Hong Qing; Zhicheng Lin
Journal:  Mol Neurobiol       Date:  2017-10-05       Impact factor: 5.590

9.  Investigating the potential influence of cause of death and cocaine levels on the differential expression of genes associated with cocaine abuse.

Authors:  Michael J Bannon; Candace L Savonen; Zachary J Hartley; Magen M Johnson; Carl J Schmidt
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

10.  A molecular profile of cocaine abuse includes the differential expression of genes that regulate transcription, chromatin, and dopamine cell phenotype.

Authors:  Michael J Bannon; Magen M Johnson; Sharon K Michelhaugh; Zachary J Hartley; Steven D Halter; James A David; Gregory Kapatos; Carl J Schmidt
Journal:  Neuropsychopharmacology       Date:  2014-03-19       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.